Peter Searle qualified with a BA in Natural Sciences from the University of Cambridge in 1977, where he specialised in Genetics in his final year. He went on to study for a PhD at the National Institute for Medical Research, Mill Hill, London, where his research focused on gene regulation. He subsequently took up a postdoctoral research position in the Department of Biochemistry, University of Washington, Seattle, USA, where his research continued the theme of gene regulation.
He returned to the UK with a Lectureship in the then Department of Cancer Studies, where he initially continued to work on gene regulation, while setting up model systems to investigate aspects of papillomavirus and Epstein Barr virus oncogenicity.
In the early 1990s he shifted his research interest to focus on development of cancer gene therapy, with particular interests both in prodrug activation gene therapy and immunotherapeutic approaches.
Jaberipour, M., Vass, S.O., Guise, C.P., Grove, J.I., Knox, R.J., Hu, L., Hyde, E.I., and Searle, P.F. (2010). Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: Effects of combining beneficial single mutations. Biochem Pharmacol 79; 102-111.
Elmetwali, T., Searle, P.F., McNeish, I., Young, L.S., and Palmer, D.H. (2010). CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer 9; 52.
Vass, S.O., Jarrom, D., Wilson, W.R., Hyde, E.I., and Searle, P.F. (2009). E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. Br J Cancer 100; 1903-1911.
Patel, P., Young, J.G., Mautner, V., Ashdown, D., Bonney, S., Pineda, R.G., Collins, S.I., Searle, P.F., Hull, D., Peers, E., et al. (2009). A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954. Mol Ther 17; 1292-1299.
Jarrom, D., Jaberipour, M., Guise, C.P., Daff, S., White, S.A., Searle, P.F., and Hyde, E.I. (2009). Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. Biochemistry 48; 7665-7672.
Young, J.G., Green, N.K., Mautner, V., Searle, P.F., Young, L.S., and James, N.D. (2008). Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis 11; 187-193.
Race, P.R., Lovering, A.L., White, S.A., Grove, J.I., Searle, P.F., Wrighton, C.W., and Hyde, E. (2007). Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954. J Mol Biol 368; 481-492.
Habib-Agahi, M., Phan, T.T., and Searle, P.F. (2007). Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 19; 1383-1394.